Live Analyst Rating Changes 2091 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stacy Ku
TD
Stacy Ku
TD Cowen
Wall Street Analyst
★★★☆☆
#1534
on 13Foresight · ranked by our own returns
40%
Success Rate
+4.0%
Average Return
6 of 15 calls profitable · -3.0% vs benchmark
📈 Across the calls we could measure, roughly 40% of Stacy Ku's ratings turned a profit when each position was held for 1 year — averaging +4.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

90 Buy 0 Hold 0 Sell
Stacy's Stock Coverage 16 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
AVTX
Avalo Therapeutics
 Jun 11, 2026 BUY Strong Buy
+229.5% avg upside
19 analysts
 — ·
SLGL
Sol-Gel Technologies
 May 29, 2026 BUY Strong Buy
+2.0% avg upside
5 analysts
 — ·
TARA
Protara Therapeutics
 May 20, 2026 BUY Strong Buy
+1119.4% avg upside
21 analysts
 — -18.1%
VRCA
Verrica Pharmaceuticals
 May 12, 2026 BUY Strong Buy
+223.7% avg upside
8 analysts
$20.00
254.56% Upside
 -8.1%
LENZ
LENZ Therapeutics
 May 11, 2026 BUY Buy
+302.1% avg upside
17 analysts
$60.00
930.90% Upside
 -31.6%
TNXP
Tonix Pharma
 May 11, 2026 BUY Strong Buy
+130.7% avg upside
7 analysts
$22.00
80.31% Upside
 -14.9%
AUPH
Aurinia Pharmaceuticals
 May 07, 2026 BUY Strong Buy
-11.6% avg upside
12 analysts
$17.00
3.03% Downside
 +8.7%
BCRX
BioCryst
 May 06, 2026 BUY Strong Buy
+100.2% avg upside
24 analysts
$30.00
228.23% Upside
 -4.5%
SUPN
Supernus Pharmaceuticals
 May 05, 2026 BUY Strong Buy
+21.5% avg upside
7 analysts
$65.00
46.23% Upside
 +0.5%
GRCE
Grace Therapeutics
 Apr 23, 2026 BUY Strong Buy
+157.9% avg upside
9 analysts
$8.00
254.00% Upside
 -0.9%
GB:0NZT
UCB SA
 Mar 19, 2026 BUY Buy
-13.3% avg upside
19 analysts
$310.00
24.22% Upside
 ·
UCBJY
UCB SA
 Mar 13, 2026 BUY Strong Buy
+12.5% avg upside
2 analysts
$175.00
23.69% Upside
 -8.2%
CNTA
Centessa Pharmaceuticals
 Nov 12, 2025 BUY Buy
-14.6% avg upside
19 analysts
 — +49.9%
VYNE
VYNE Therapeutics
 Nov 07, 2025 BUY Strong Buy
+2001.2% avg upside
9 analysts
$2.00
207.69% Upside
 +86.4%
DMAC
Diamedica Therapeutics
 Oct 30, 2025 BUY Strong Buy
+151.8% avg upside
12 analysts
 — -15.6%
MLTX
MoonLake Immunotherapeutics
 Feb 26, 2025 BUY Strong Buy
+37.7% avg upside
20 analysts
 — -58.3%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stacy Ku — Frequently Asked Questions
How accurate are Stacy Ku's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Stacy's ratings were profitable over a one-year hold, with an average return of +4.0% per rating, or -3.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Stacy ranked on 13Foresight?
Stacy Ku is currently ranked #1534 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stacy cover?
Stacy most recently has ratings on AVTX, SLGL, TARA, VRCA, LENZ, TNXP, AUPH, BCRX, SUPN, GRCE, GB:0NZT, UCBJY and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.